The GeneSight Psychotropic test represents a significant advancement in precision medicine for mental health conditions. Developed by Myriad Neuroscience, this pharmacogenomic test analyzes how variations in multiple genes may influence an individual's response to certain FDA-approved medications commonly prescribed for depression, anxiety, and other psychiatric conditions. As mental health challenges continue to rise globally, with research showing a threefold increase in adults experiencing psychological distress, innovative tools like GeneSight offer healthcare providers additional information to inform treatment decisions.
The Science Behind GeneSight
GeneSight employs a combinatorial pharmacogenomic approach, evaluating multiple genes that impact how the body metabolizes psychiatric medications. Unlike single-gene testing, which focuses on individual genetic variations, the combinatorial approach provides a more comprehensive understanding of potential gene-drug interactions. The test primarily examines CYP2C19 and CYP2D6 genes, which are involved in how the body metabolizes medications commonly used to treat depression and other mental illnesses.
Recent research published in Psychiatry Research has demonstrated that this combinatorial approach is superior to single-gene testing in predicting medication blood levels and patient outcomes. The analysis showed that the GeneSight test more accurately predicts blood drug concentrations and identifies more patients with significant gene-drug interactions who would be missed by single-gene testing.
According to Dr. Mark Pollack, chief medical officer at Myriad Neuroscience, "This analysis demonstrates that the combinatorial approach of the GeneSight test more accurately predicts blood drug levels and identifies more patients with significant gene-drug interactions who would be missed by single-gene testing."
Clinical Evidence Supporting GeneSight
The clinical validity of the GeneSight test has been supported by multiple peer-reviewed studies. The GUIDED study, the largest pharmacogenomic randomized controlled trial in mental health, demonstrated that patients whose doctors received GeneSight results had significantly improved response and remission rates from depression compared to treatment as usual.
An earlier study, also published in Psychiatry Research in May 2020, demonstrated that the combinatorial approach available in the GeneSight Psychotropic test was better at predicting citalopram and escitalopram blood concentrations when compared to single-gene testing. This study included two types of analyses that highlighted the superior predictive ability of combinatorial pharmacogenetic testing to determine variation in medication blood levels, potentially resulting in improved patient outcomes.
Lead author Anthony J. Rothschild, MD, the Irving S. and Betty Brudnick Endowed Chair and Professor of Psychiatry at the University of Massachusetts Medical School, stated, "Our analysis demonstrated the superior ability of combinatorial pharmacogenetic testing to predict variation in medication blood levels may result in improved patient outcomes. We believe this study provides compelling evidence of the clinical validity of the combinatorial pharmacogenomic test for patients with major depressive disorder, who have at least one prior medication failure."
The Process of Implementing GeneSight Testing
The GeneSight test is administered through a straightforward process that can now be completed at home using a patient collection kit. The kit must still be ordered by a licensed healthcare provider, who can request it through the secure, online GeneSight portal. The kit is then sent directly to the patient, who follows step-by-step instructions to collect a DNA sample using a buccal (cheek) swab.
After collecting the sample, the patient places the swab into a confidential, prepaid and preaddressed shipping envelope to return it to the Myriad Neuroscience CLIA and CAP Accredited lab for processing. The results are typically available to the ordering clinician via the secure clinician portal in approximately two days.
This process was developed to accommodate the growing need for remote access and innovative solutions in mental healthcare, particularly as more clinicians practice telemedicine. Mark S. Verratti, president of Myriad Neuroscience and Myriad Autoimmune, explains, "At the same time, more clinicians are practicing telemedicine out of necessity to continue to provide care to their patients. To accommodate this growing need for remote access and innovative solutions, we created this easy-to-use patient collection kit. This process allows clinicians to continue to use the GeneSight test as one tool at their disposal when developing a treatment plan for their patients suffering from depression or anxiety."
Benefits of Combinatorial Pharmacogenomic Testing
The GeneSight test offers several potential benefits in psychiatric treatment. By providing information about how a patient's genetic variations may impact their response to certain medications, the test can help healthcare providers make more informed prescribing decisions. This personalized approach may reduce the trial-and-error process often associated with finding effective psychiatric medications, potentially leading to improved outcomes and reduced side effects.
Dr. Pollack emphasizes that "combinatorial pharmacogenomics like the GeneSight test should become the standard-of-care to help physicians understand gene-drug interactions that could improve care for people with depression, anxiety and other conditions."
The test has been administered to more than one million patients by tens of thousands of clinicians, providing genetic information that is unique to each patient. It supplements other information considered by a doctor as part of a comprehensive medical assessment, rather than replacing clinical judgment or other diagnostic tools.